3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
762
Lung Neoplasms
339
Ovarian Neoplasms
318
Breast Neoplasms
277
Fallopian Tube Neoplasms
158
Triple Negative Breast Neoplasms
143
Small Cell Lung Carcinoma
140
Neoplasms
134
Squamous Cell Carcinoma of Head and Neck
122
Carcinoma, Ovarian Epithelial
114
Neoplasm Metastasis
84
Head and Neck Neoplasms
80
Endometrial Neoplasms
76
Uterine Cervical Neoplasms
70
Esophageal Neoplasms
70
Adenocarcinoma of Lung
68
Neuroblastoma
55
Central Nervous System Neoplasms
52
Lymphoma, Large B-Cell, Diffuse
49
Carcinoma
49
Brain Neoplasms
48
Recurrence
47
Prostatic Neoplasms
44
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Urinary Bladder Neoplasms
42
Esophageal Squamous Cell Carcinoma
41
Lymphoma
39
Melanoma
35
Carcinoma, Squamous Cell
33
Lymphoma, Non-Hodgkin
31
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration-Resistant Prostate Cancer
×
Carboplatin
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled